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Overexpression of miR-26a-2 in human liposarcoma is
correlated with poor patient survival
DH Lee1,2, S Amanat1, C Goff1, LM Weiss3, JW Said2, NB Doan2, A Sato-Otsubo4, S Ogawa4, C Forscher1 and HP Koeffler1,5
Approximately 90% of well-differentiated/de-differentiated liposarcomas (WDLPS/DDLPS), the most common LPS subtype, have
chromosomal amplification at 12q13-q22. Many protein-coding genes in the region, such as MDM2 and , have been studied as
potential therapeutic targets for LPS treatment, with minimal success. In the amplified region near the MDM2 gene, our single
nucleotide polymorphism (SNP) array analysis of 75 LPS samples identified frequent amplification of miR-26a-2. Besides being in the
amplicon, miR-26a-2 was overexpressed significantly in WDLPS/DDLPS (Po0.001), as well as in myxoid/round cell LPS (MRC)
(Po0.05). Furthermore, Kaplan–Meier survival analysis showed that overexpression of miR-26a-2 significantly correlated with poor
patient survival in both types of LPS (Po0.05 for WDLPS/DDLPS; Po0.001 for MRC). Based on these findings, we hypothesized that
miR-26a-2 has an important role in LPS tumorigenesis, regardless of LPS subtypes. Overexpression of miR-26a-2 in three LPS cell
lines (SW872, LPS141 and LP6) enhanced the growth and survival of these cells, including faster cell proliferation and migration,
enhanced clonogenicity, suppressed adipocyte differentiation and/or resistance to apoptosis. Inhibition of miR-26a-2 in LPS cells
using anti-miR-26a-2 resulted in the opposite responses. To explain further the effect of miR-26a-2 overexpression in LPS cells,
we performed in silico analysis and identified 93 candidate targets of miR-26a-2. Among these genes, RCBTB1 (regulator of
chromosome condensation and BTB domain-containing protein 1) is located at 13q12.3-q14.3, a region of recurrent loss of
heterozygosity (LOH) in LPS. Indeed, either overexpression or inhibition of RCBTB1 made LPS cells more susceptible or resistant to
apoptosis, respectively. In conclusion, our study for the first time reveals the contribution of miR-26a-2 to LPS tumorigenesis,
partly through inhibiting RCBTB1, suggesting that miR-26a-2 is a novel therapeutic target for human LPS.
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INTRODUCTION
Human liposarcoma (LPS) is the most common soft-tissue
sarcoma, comprising 24–45% of the total soft-tissue sarcomas.1,2
Surgical resection can effectively manage primary local disease,
but metastatic disease cannot be cured either by surgery,
chemotherapy or radiotherapy. Despite its high occurrence,
the molecular causes of this sarcoma are poorly understood.
LPS is grouped in three major subtypes depending on their
histopathological characteristics:1,2 (1) Well-differentiated/
de-differentiated (WDLPS/DDLPS), (2) myxoid/round cell LPS
(MRC) and (3) pleomorphic LPS. WDLPS/DDLPS is the most
common subtype and is characterized by chromosomal ampli-
fication at 12q13-q22, which contains the MDM2 and CDK4 genes
in 90% of the cases. Laboratory investigators have focused on
blocking the function of these amplified genes with Nutlin 3a
and several novel compounds, respectively.1–4 To date, these
approaches have shown disappointing clinical outcomes.
For a better understanding of LPS, we performed genome-wide
copy number (CN) analysis of 75 human LPS samples, using single
nucleotide polymorphism (SNP) array. Our preliminary study
found that miR-26a-2 is amplified and highly expressed in LPS.
MicroRNA (miRNA) is a short, non-coding RNA that can regulate
the expression of multiple target genes in a cell-type-specific
manner.5 miRNAs classically interact with the 30-untranslated
region (UTR) region of the target mRNAs, resulting in the
degradation of the mRNA and/or the inhibition of translation of
the target gene. Changes in the expression of miRNAs often occur
with malignant transformation. For example, 11% of glioblastoma
multiforme (GBM) have amplification and overexpression of the
miR-26a-2.6,7 This miRNA is known to target the tumor-suppressor
genes PTEN and RB1.6,7 Therefore, targeting of dysregulated
miRNA is an appealing new option for cancer therapy.5
In this study, we investigated the in vitro effect of miR-26a-2 on
the proliferation and survival of LPS cells. We also identified a
novel, LPS-specific target protein of miR-26a-2 that could partly
explain the effect of miR-26a-2 in LPS cells.
RESULTS
Recurrent genomic aberrations in human LPS
Characteristics of 72 human LPS patients, whose DNA was
subjected to SNP array analysis, are summarized in Table 1.
More than half of the tumor specimens were WDLPS/DDLPS
(43 samples, 57% of all the samples), followed by MRC (22
samples, 29%). Only three samples represented pleomorphic LPS.
The samples were from 39 males (52% of the patients) and 29
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females (39%). Average age of the patients was 57±15 years,
ranging from 14 to 86 years. Median follow-up period was 36
months.
SNP array analysis identified 6107 total CN) changes, including
those successfully identified recurrent genomic changes pre-
viously reported (Table 2).8 The most distinct feature of the CN
changes in LPS was the dominance of CN gains over CN losses.
Nearly 91% of the CN changes were CN gains (total 5532 CN
gains). Many of these CN gains were identified on chromosome 12
(1968 gains), especially at chromosome 12q13-q22 (757 gains)
(Figures 1a and b). Sixty-six percent of the samples showed
various levels of CN gain in the region (48 samples). When we
considered only WDLPS/DDLPS, the percentage of CN gains
surged to 83% (35 samples). Other recurrent regions of CN gain
were also identified (Table 2). Recurrent CN gain at 1q21-q24
occured in 40% of the samples (29 samples), followed by 5p13-
p15 (24 samples, 33%) and 6q22-q24 (23 samples, 32%).
Close examination of CN gain in 12q13-q22 identified two
distinct amplicons, MDM2 amplicon (A1) and miR-26a-2 amplicon
(A2), which were almost always present in the samples with 12q
amplification (Figure 1a). The miR-26a-2 amplicon, also commonly
known as CDK4 amplicon,9 showed a strong correlation with the
appearance of the MDM2 amplicon. Among 41 samples with a
miR-26a-2 amplicon (mostly WDLPS/DDLPS), 36 of these samples
had an accompanied MDM2 amplicon (85%) (Table 3). Likewise,
among 28 samples without a miR-26a-2 amplicon (mostly MRC),
26 samples also did not have a MDM2 amplicon (93%). A w2 test
proved that the occurrence of these two amplicons are not
independent, but are strongly correlated (Po0.001).
In addition to total CN changes, SNP array analysis revealed
recurrent regions of loss of heterozygosity (LOH) in LPS
(Figures 1c–e). LOH occurs by either deletion alone, or deletion
of one allele followed by duplication of the other allele (CN-neutral
LOH). Genes in the LOH region often have important roles in
cancer biology and are frequently mutated.10 This is especially the
case with CN-neutral LOH where one normal allele is lost, and the
other allele is mutated and then duplicated.
A total of 575 events (9%) of LOH by deletion occurred in the 75
LPS samples (Table 2). LOH by deletion at 13q12.3-a14.3 was the
most frequent change (9 samples, 12%), with a homozygous
deletion in some of those cases (Supplementary Table S1).
Regarding CN-neutral LOH, a total of 110 events occured in 23
LPS samples (Supplementary Table S2). Nearly half of the
CN-neutral LOH (50 events, 45%) were found in only three
samples (LPS19, LPS44 and LPS63). The most recurrent region of
CN-neutral LOH was Xp22.33-p21.1 (six events), followed by
2q31.1, 12p11.22-q12, 13q12.3-q14.3, 14q12, 17q11.1-q11.2 and
Xq26.2-qter (all five events). Overall, the 13q12.3-q14.3 region
showed the highest LOH frequency in LPS.
Overexpression of miR-26a-2 and its correlation with poor patient
survival
CN gains of the miR-26a-2 amplicon identified by SNP array were
validated by genomic quantitative PCR (qPCR) (Figure 2a). The
median CN of the miR-26a-2 gene was significantly higher than
that of the non-matched normal fat tissues in WDLPS/DDLPS
Table 1. Characteristics of 72 patients, whose LPS samples were
studied. Total number of patients n¼ 72
Characteristics Value
Age
Mean±s.d. 57±15 Years
Range 14B86 Years
Gender
Male 39 (52%)
Female 29 (39%)
Unknown 4 (9%)
Histologic subtype
WD 28 (37%)
DD 15 (20%)
MRC 22 (29%)
P 3 (4%)
Mixed/NOS 4 (9%)
Median follow-up 36 Months
Abbreviations: DD, dedifferentiated LPS; LOH, loss of heterozygosity; MRC,
myxoid/round cell LPS; NOS, not otherwise specified; P, pleomorphic LPS;
WD, well-differentiated LPS.
Table 2. Recurrent genomic changes in human liposarcomas (LPS)
Cytoband WD
(n¼ 28)
DD
(n¼ 15)
MRC
(n¼ 22)
P
(n¼ 3)
NOS
(n¼ 5)
Total
(n¼ 73)
CN gain
12q13-q22 22 (79%) 14 (93%) 7 (32%) 1 4 48 (66%)
1q21-24 14 (50%) 6 (40%) 6 (27%) 2 1 29 (40%)
5p13-p15 6 (21%) 11 (73%) 4 (18%) 1 2 24 (33%)
6q22-q24 9 (32%) 6 (40%) 4 (18%) 2 2 23 (32%)
CN loss
13q12.13-q14.3 4 (14%) 1 (7%) 2 (9%) 1 1 9 (12%)
CN-neutral LOH
Xp22.32-p21.1 2 (7%) 2 (13%) 2 (9%) 0 0 6(8%)
2q31.1 2 (7%) 2 (13%) 0 (0%) 1 0 5 (7%)
12p11.22-q12 1 (4%) 1 (7%) 1 (5%) 1 1 5 (7%)
13q12.3-q14.3 2 (7%) 1 (7%) 1 (5%) 1 0 5 (7%)
14q12 2 (7%) 1 (7%) 1 (5%) 1 0 5 (7%)
17q11.1-q11.2 1 (4%) 1 (7%) 1 (5%) 1 1 5 (7%)
Xq26.2-qter 1 (4%) 2 (13%) 2 (9%) 0 0 5 (7%)
Abbreviations: CN, copy number; DD, dedifferentiated LPS; LOH, loss of heterozygosity; MRC, myxoid/round cell LPS; NOS, not otherwise specified;
P, pleomorphic LPS; WD, well-differentiated LPS.
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(Po0.001) and MRC (Po0.05). DDLPS showed the highest median
CN gain, followed by WDLPS and MRC (Figure 2b).
Overexpression of miR-26a-2 gene was identified by Quantita-
tive reverse-transcription real-time PCR (qRT-PCR) (Figures 2c and
d). The significant increase in the median expression level was
found in DDLPS (Po0.001) and MRC (Po0.001), but not in WDLPS
(P¼ 0.415), although some WDLPS samples did show high
expression of the gene. The expression level of the miR-26a-2
gene, however, was not always CN-driven. In DDLPS, expression
level of miR-26a gene strongly correlated with the CN status of the
gene, with a Pearson’s correlation coefficient (R) of 0.53. In
contrast, WDLPS showed no significant increase of miR-26a-2
expression level, although a significant increase of the median CN
gain of miR-26a-2 gene occurred (R¼ 0.16). Furthermore, MRC
showed a significantly increased expression of the miR-26a-2 gene
even though this group had the lowest median CN gain of the
miR-26a-2 gene (R¼ 0.21). Overall, overexpression of miR-26a-2
gene was seen in the majority of the samples, but the CN-driven
overexpression occured only in DDLPS.
We examined the correlation of miR-26a-2 expression level to
known clinical parameters. First, we performed paired analysis of
five LPS samples and their matched normal fat tissues (Figure 3a).
Three out of five samples (LPS12, LPS19 and LPS22) showed
significantly increased expression level of the miR-26a-2 compared
with levels of the gene in matched normal fat tissue (Po0.05 for
all). Individuals from these three LPS samples had a worse
prognosis than the other two individuals (LPS11 and LPS13)
without significant changes in the miR-26a-2 expression level
compared with matched normal fat control. Therefore, we
expanded the analysis to all samples with patient survival data.
Kaplan–Meier survival analysis was performed on 17 patients
with WD/DDLPS and 22 individuals with MRC. Patients whose
tumors had higher miR-26a-2 expression level had a worse
prognosis in both the WD/DDLPS (Po0.05) and MRC cohorts
(Po0.001) (Figures 3b and c). Other clinical parameters such as
age and gender did not show any significant correlation with the
levels of miR-26a-2 (data not shown).
Effect of miR-26a-2 on growth and survival of LPS cells
To examine the function of miR-26a-2 in LPS cells, we used three
LPS cell lines, SW872, LPS141 and LP6, which showed low,
medium and high endogenous expression of miR-26a-2, respec-
tively (Supplementary Figure S1A). For each cell line, we
established stable overexpression clones of miR-26a-2
(Supplementary Figure S1B). Overexpression of miR-26a-2 in these
LPS cells stimulated the growth and survival of LPS cells with
varied outcomes (Supplementary Figures S1C–F).
We also examined the effect of inhibition of miR-26a-2 using
anti-miR-26a-2 oligos. SW872 cells were excluded due to their
minimal endogenous expression of miR-26a-2. Anti-miR-26a-2
oligos successfully inhibited the expression of miR-26a-2 by
around 50% in both LPS141 and LP6 cells (Supplementary Figure
S1G). Decreased miR-26a-2 levels inhibited the growth and
survival of LPS cells with varied outcomes (Supplementary
Figures S1H-K).
Chr13
13q12.3-q14.3
Chr13
Allelic CN change
Hetero SNP calls
Total CN
CN gain
(red lines)
CN loss
(green lines)
Chr12
A1A2
12q13-q22
Chr12
Chr13 (CN-LOH)
miR-26a-2
RCBTB1
MDM2
Figure 1. Recurrent genomic changes in human LPS. SNP array results of 75 LPS samples. Two representative genomic changes in human LPS
at 12q13-q22 (panels a and b) and at 13q12.3-q14.3 (panels b–e) are shown. (a) Integral view of chromosome 12 demonstrates recurrent CN
gains of 12q13-q22 (red). Each bar indicates the region of CN changes in each sample. Two of the most recurrent amplicons are shown:
Amplicon A1 is centered on MDM2 gene. Amplicon A2 contains miR-26a-2 gene. (b) CNAG output of chromosome 12 for sample LPS2 is shown
as an example. (c) Integral view of chromosome 13 showing recurrent LOH by deletion at 13q12.3-q14.3 (green). (d) Integral view of
chromosome 13 showing recurrent CN-LOH of 13q12.3-q14.3 (black). (e) CNAG output of chromosome 12 for sample LPS44 is shown as an
example.
Table 3. Status of MDM2 amplicon (amplicon A1) and miR-26a-2
amplicon (amplicon A2) as determined by SNP array analysis of 75
human LPS samples
Amplicon Frequency WD DD MRC P NOS
Amplicon A1 and
A2
39 (52%) 16 14 6 0 3
Amplicon A1 only 5 (7%) 4 0 0 1 0
Amplicon A2 only 2 (3%) 1 0 1 0 0
No amplicon 26 (35%) 6 1 14 2 3
Unknown 3 (4%) 1 0 1 0 1
Total 75 (101%)
Abbreviations: DD, dedifferentiated LPS; LOH, loss of heterozygosity; MRC,
myxoid/round cell LPS; NOS, not otherwise specified; P, pleomorphic LPS;
WD, well-differentiated LPS.
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Modulation of miR-26a-2 expression also affected genes
important for adipocyte differentiation. SW872 and LP6 clones
with overexpression of miR-26a-2 showed significant inhibition of
mRNA expression of these genes (Po0.05) (Figures 4a and b).
Western blot results also showed a modest downregulation of
expression of C/EBPa and C/EBPb proteins in the SW872 and LP6
cells, respectively. Inhibition of miR-26a-2 using anti-miR-26a-2 did
not change the mRNA expression level of these genes (data not
shown), but caused upregulation C/EBPa, C/EBPb and PPARg
proteins in the LPS141 and LP6 cells, as noted on western blot
(Figure 4c). Despite the clear changes in the differentiation marker
genes, forced differentiation of the clones using differentiation
media did not induce terminal differentiation, indicating a block in
this pathway (data not shown).
Interestingly, modulation of miR-26a-2 in the LPS cells affected
their resistance to apoptotic stress. miR-26a-2 overexpression
clones of SW872 and LP6 cells had 41±3 and 59±4% apoptosis,
respectively, after apoptotic stress compared to 51±5 and
67±7% of the empty vector control cells, respectively (Po0.05
for both) (Figure 4d). The same experiments were repeated except
that miR-26a-2 was inhibited by using anti-miR-26a-2 oligonucleo-
tides (Figure 4e). After exposure to apoptotic stress, 28±4% of
LPS141 cells treated with anti-miR-26a-2 oligos became apoptotic,
compared with 23±3% of cells treated with scrambled oligo
control (Po0.05). Likewise, 27±2% of the LP6 cells treated with
anti-miR-26a-2 oligo became apoptotic, compared with 20±2% of
cells treated with scrambled oligos control (Po0.05).
Identification of target proteins of miR-26a-2 in LPS
PTEN and RB1 are well-known tumor-suppressor genes as well as
known targets of miR-26a-2.6,7 In LPS cells, we could not find
evidence that either PTEN or RB1 was regulated by miR-26a-2
(Supplementary Figure S2). Both PTEN and RB1 did not change,
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Figure 2. Changes in CN status and RNA expression level of miR-26a-2 gene in human LPS samples. (a) CN of miR-26a-2 gene in LPS
determined by genomic qPCR. CN changes relative to the CN of normal human adipose tissue samples (N) are shown. Samples are grouped by
LPS subtype: MRC¼myxoid/round cell subtype; WD¼well-differentiated subtype; DD¼dedifferentiated subtype; n¼ sample number.
Experiments were repeated in triplicates to ensure accuracy. Data represent mean CN±s.d. (b) Box-whisker plot showing summary of data in
panel (a). Asterisks (* and **) indicate P-valueso0.05 and 0.001 by t-test, respectively. (c) RNA expression level of miR-26a-2 gene determined
by qRT-PCR. Expression levels relative to the expression level in normal human adipose tissue samples are shown. Data represent mean RNA
expression±s.d. (d) Box-whisker plot showing summary of data in panel (c). (e) Pearson’s correlation study of the CN change and mRNA
expression level of miR-26a-2 gene. R represents Pearson’s correlation coefficient. R value 40.5 is considered significant.
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compared with the control cells in the presence of forced
expression of miR-26a-2 or anti-miR-26a-2 in LPS cells. Likewise,
the phosphorylation status of Akt at S473, a PTEN target, did not
change as U87 GBM cells did in response to the changes in miR-
26a-2 level.
This led us to search for new targets of miR-26a in LPS cells. We
performed in silico analysis to identify putative miR-26a-2-binding
sites using five miRNA target-prediction webservers.11–15 Ninety-
three candidate genes were selected which were predicted as
targets of miR-26a-2 by more than three webservers
(Supplementary Table S3). The list successfully included all known
targets of miR-26a-2 gene, such as PTEN and RB1. Comparison of
this list with our SNP array data suggested that RCBTB1 (regulator
of chromosome condensation and BTB domain-containing
protein 1) at 13q12.3-q14.3, a recurrent region of LOH in LPS
cells, may be a putative target of miR-26a-2 in LPS. In addition,
homozygous deletion of RCBTB1 in one of our primary LPS tumor
samples (LPS44, Supplementary Table S1) also suggested that LPS
cells want to lower or eliminate the expression of this gene.
Dual luciferase reporter assay confirmed that miR-26a-2 could
bind to the putative binding site in the RCBTB1 30-UTR and
achieved a B50% knockdown of the luciferase gene (Figures 5a
and b). Point mutations at the miR-26a-2-binding site partially
restored the luciferase activity to the level of empty vector control,
indicating that the binding was site-specific.
To validate further that RCBTB1 is regulated by miR-26a-2 in
LPS cells, we examined if RCBTB1 responded to the changes in
miR-26a-2 expression level. RCBTB1 is known as a regulator of the
DNA damage/repair pathway and apoptosis.16 Under apoptotic
stress, RCBTB1 and its downstream target GADD45a (growth arrest
and DNA-damage-inducible protein a) are known to be
upregulated.16 Under apoptotic stress, the level of upregulation
of RCBTB1 and GADD45a in miR-26a-2 overexpression clones of
SW872 and LP6 cells was lower than that of the similarly
stimulated empty vector control cells (Figure 5c). Likewise, under
the same culture conditions, the level of upregulation of RCBTB1
and GADD45a in LPS141 and LP6 cells transfected with anti-
miR-26a-2 was higher than the level in scrambled oligo control
cells (Figure 5d). From these results, we concluded that RCBTB1 is
indeed the target of miR-26a-2 in LPS cells.
Role of RCBTB1 in LPS cells
As expected, overexpression of RCBTB1 made LPS cells more
susceptible to apoptotic stress (Figures 6a–c). Expression of
RCBTB1 alone increased the number of apoptotic cells from
8±1 to 26±3% in LPS141 cells, and from 6±1 to 24±3% in LP6
cells (Po0.05). With apoptotic stress, the increase was even more
apparent. The number of apoptotic cells under apoptotic stress
increased from 42±5 to 71±7% in LPS141 cells, and from 47±3
to 77±10% in LP6 cells (Po0.05).
We also established stable clones of SW872 and LPS141 cells
expressing short hairpin RNA (shRNA) against RCBTB1, which
significantly decreased the levels of RCBTB1 (Figure 6d). Both
shRNA clones showed higher resistance to apoptotic stress
(Figures 6e and f). Under apoptotic stress, the number of apoptotic
cells of the SW872 shRNA clones increased from 3±0.2 to 44±3%
(SH1), and from 5±0.2 to 45±2% (SH2), compared with 6±0.3 to
50±3% in the scrambled control cells (Po0.05). Likewise, the
number of apoptotic cells of LPS141 shRNA clones increase from
2±0.2 to 12±2% (SH1), and from 3±0.1 to 16±4% (SH2),
compared with the change from 5±1 to 24±3% in scrambled
control cells (Po0.05).
To validate further the inhibition of RCBTB1 by miR-26a-2, we
cotransfected the miR-26a-2 and RCBTB1 expression vectors in
SW872 cells (Figure 7). We constructed a new RCBTB1 expression
vector containing 30-UTR miR-26a-2-binding site (RCBTB1-3UTR)
and compared the results with the one without 30-UTR (RCBTB1).
Cotransfection of miR-26a-2 with RCBTB1-3UTR significantly
decreased the number of apoptotic cells from 54±8 to 36±4%
(Po0.05). Cotransfection of miR-26a-2 with RCBTB1 also showed a
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Figure 3. Correlation between miR-26a-2 expression and patient
survival. (a) Paired analysis of LPS samples with matched normals.
Five LPS samples with matched normals were analyzed for the
correlation of miR-26a-2 expression and its relationship to patient
survival (Supplementary Table S4). Each bar represents average
relative expression±s.d. Asterisk (*) indicates P-value o0.05 by
t-test. NS¼not significant. (b) Kaplan–Meier survival analysis of LPS
patients. Patients were divided into two groups according to their
miR-26a expression level, using the data in Figure 2c. Median
expression fold change (10-fold) was used as a cutoff value. (low,
o10-fold increase in miR-26a-2 expression; high, X10-fold).
Asterisks (**) indicate P-value o0.001 by log-rank test. WD/DD¼
well-differentiated/dedifferentiated LPS subtype; MRC¼myxoid/
round cell LPS subtype.
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small decrease in the number of apoptotic cells from 68±7 to
58±12%, but was not statistically significant (P¼ 0.14). In
addition, the inhibitory effect of miR-26a-2 was greater when
the apoptosis was induced by RCBTB1-3UTR, rather than RCBTB1
(34±6 versus15±2, Po0.05).
DISCUSSION
In this study, we analyzed the genomic aberrations of 75 human
LPS and identified several new recurrent regions of genomic
abnormalities, most notably the recurrent LOH in 13q12.3-q14.3.
This region is well known for the high prevalence of tumor-
suppressor genes such as RB1 and miR-15a/16-1, which are
frequently mutated or deleted in many cancers.17 However,
its importance in LPS tumorigenesis has not been reported.
Our observation can be attributed to the use of SNP array
combined with AsCNAR algorithm that can differentiate allele-
specific CN changes such as CN-neutral LOH.18 Indeed, half of the
LOHs in 13q12.3-q14.3 were CN-neutral LOH, rather than LOH by
deletion. Unlike CN gain at 12q13-q22, which was predominantly
found in DDLPS, LOH at 13q12.3-q14.3 was not subtype-specific,
indicating that genes in the region contributed to LPS
tumorigenesis in a more general way. Recently, Barretina et al.19
reported CN-neutral LOH events in LPS, but did not identify
recurrent regions, partly due to the low number of events. Their
group also reported somatic mutations in LPS, but none of
these genes was located at 13q12.3-q14.3.19 Extensive exon
sequencing of the genes in the region may identify new somatic
mutations in LPS.
Interestingly, two of the most recurrent genomic changes in LPS
(CN gain in 12q13-q22 and LOH in 13q12.3-q14.3) resemble the
recurrent genomic changes in chronic lymphocytic leukemia.
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Trisomy chromosome 12 or CN loss at 13q12.3-q14.3 often occur
in chronic lymphocytic leukemia, and usually occur in a mutually
exclusive fashion.16,20 Our statistical analysis could not identify
such a correlation in LPS, but many samples with CN loss at
13q12.3-q14.3 often lacked the CN gain at 12q13-q22 (data not
shown). Increasing the sample size may identify a possible
correlation between the two genomic changes in LPS.
Among the many genes in the 12q13-q22 region, we focused
on the miR-26a-2 gene for several reasons: first, many protein-
coding genes in the region have been studied as potential
therapeutic targets for LPS treatment, with minimal success to
date. Second, the miR-26a-2 amplicon occurred nearly as
frequently as the MDM2 amplicon. Third, the oncogenic role of
miR-26a-2 in GBM could suggest a similar role for the gene in LPS.
Indeed, overexpression of miR-26a-2 enhanced the growth and
survival of the LPS cells with varied outcomes. However, the
stimulatory pathway engaged by overexpression of miR-26a-2 in
LPS cells seems to differ from the mechanism previously reported
in GBM cells. In GBM, overexpression of miR-26a-2 directly inhibits
the key growth signaling proteins such as PTEN and RB1.7 In LPS,
miR-26a-2 overexpression had little effect on these proteins for
unclear reasons. Rather, miR-26a-2 inhibited the key proteins
related to adipocyte differentiation and apoptosis, which indirectly
promoted the growth and survival of LPS cells. Inhibition
of RCBTB1 can partly explain the effect of miR-26a-2 in LPS cells.
As a regulator of the DNA damage/repair pathway and
apoptosis,16 inhibition of RCBTB1 by overexpression of miR-26a-
2 made LPS cells more resistant to apoptotic stress. However,
RCBTB1 had little effect on the differentiation of adipocyte (data
not shown), which implies the existence of another major target
protein of miR-26a-2 in LPS cells.
Interesting but unexplored is our observation that the primary
DDLPS tumor sample (LPS44) with a homozygous deletion of
RCBTB1 had no amplification of chromosome 12, which is very
unusual in DDLPS. It is one of the samples that we noted,
suggesting a possible correlation of CN loss in 13q12.3-q14.3 and
the CN gain at 12q13-q22. The diminished expression of RCBTB1
may substitute for the overexpression of miR-26a-2 in LPS cells.
Clearly, further studies are needed to examine the significance of
this relation.
Next to RCBTB1 is RCBTB2, which is also homozygously deleted
in LPS44. Despite their proximity and structural similarity, RCBTB1
and RCBTB2 are paralogs that share little biological function.
Unlike RCBTB1, RCBTB2 is not deleted recurrently in chronic
lymphocytic leukemia and has no miR-26a-2-binding site in its
30-UTR region. Therefore, it is unlikely that RCBTB2 has a similar
role as RCBTB1 in LPS. However, its interaction with COPS4
(constitutive photomorphogenic homolog subunit 4) suggests
that RCBTB2 may have an important role by regulating the
phosphorylation of p53 and c-Jun.21
In conclusion, our SNP array results contribute to our global
molecular characterization of human LPS. The strong association
of miR-26a-2 expression level with patient survival suggests the
contribution of miR-26a-2 to LPS tumorigenesis. We also identified
a new target gene of miR-26a-2, RCBTB1. Taken together,
new therapeutic targets have been identified for this pernicious
cancer.
MATERIALS AND METHODS
Primary human LPS specimens
Seventy-two primary human LPS tumor tissues, as well as clinical data were
obtained from various sources with IRB approval from each institution
(Supplementary Table S4). Nine LPS samples (LPS1–LPS9, numbers in order
of acquisition) were provided by Dr Jonathan Said at the University of
California (Los Angeles, CA, USA). Fourteen samples (LPS11–LPS24) were
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Figure 5. RCBTB1 as a target of miR-26a-2 in LPS cells. (a) Schematic diagram of RCBTB1 30-UTR showing seed sequence (50-UACUUGAA-30) of
miR-26a-2-binding site. In mutant, seed sequence was mutated to 50-ACAUUUAG-30 by site-directed mutagenesis. (b) Luciferase assay results.
pGL3-Promoter-RCBTB1 30-UTR luciferase reporter vector was cotransfected with either miR-26a-2 expression vector (26A2) or empty vector
control (EV) in 293T cells. After 48 h, cells were harvested and luciferase activity was quantified. Fluc/Rluc¼ Firefly luciferase/Renilla luciferase.
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exposed to apoptotic stress (nocodazole) for 48 h before harvesting. GAPDH was used as a loading control. (d) Levels of RCBTB1 and GADD45a
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Asterisk (*) indicate P-value o0.05 by t-test. NS, not significant.
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purchased from the Tumor Repository at Yale University School of
Medicine (New Haven, CT, USA). Twenty-eight samples (LPS25–LPS52)
were obtained from Dr Lawrence M Weiss at City of Hope (Duarte, CA,
USA). Twenty-one samples (LPS53–LPS75) were from Dr Eng Chon Boon at
the NUHS Tissue Repository of the National University of Singapore (NUS,
Singapore). Three DNA samples (LPS10, LPS56 and LPS60) were partially
degraded and have been excluded from the study.
Thirteen matched and non-matched normal fat tissues were also
obtained (Supplementary Table S4). Five non-matched normal fat tissues
(F1–F5) were provided by Dr Jonathan Said. Six samples (LPS11, 12, 13, 15,
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19 and 22) obtained from the Yale tumor repository had matched normal
fat tissues from the same patients. They were subjected to paired analysis.
Two samples (LPS55 and LPS60) were from NUS, which had matched
normal samples.
Human LPS cell lines
Three human LPS cell lines (SW872, LPS141 and LP6) were included in the
study: SW872 cells were purchased from American Tissue Type Culture
Collection (ATCC, Rockville, MD, USA); LPS141 and LP6 cells were provided
by Dr Christopher DM Fletcher at Brigham and Women’s Hospital
(Boston, MA, USA).22 All three LPS cell lines were maintained in RPMI
medium (Mediatech Inc, Herndon, VA, USA) supplemented with 15% fetal
bovine serum (Atlanta Biological, Lawrenceville, GA, USA) in a humidified
incubator at 37 1C supplied with 5% CO2. Only cells in the exponential
growth phase were used in the study.
SNP array analysis
SNP array analysis was performed using GeneChip human mapping SNP
array (Affymetrix, Santa Clara, CA, USA). Briefly, genomic DNA from
75 human LPS samples were purified using DNeasy DNA purification kit
according to the manufacturer’s protocol (Qiagen, Valencia, CA, USA) and
hybridized to Affymetrix 250K NspI SNP array. GeneChip Fluidics Station
400 and GeneChip scanner 3000 were used to produce raw data, which
were processed and analyzed by CN analyzer for Affymetrix GeneChip
(CNAG 2.0) using allele-specific CN analysis, employing anonymous
reference (AsCNAR) algorithm.18
Quantitative reverse-transcription real-time PCR
Total RNAs from all LPS samples were purified using miRNeasy RNA
purification kit according to the manufacturer’s protocol (Qiagen).
First-strand cDNA was made using iScript cDNA construction kit according
to the manufacturer’s protocol (Bio-Rad, Hercules, CA, USA). qRT-PCR was
performed with Bio-Rad SsoFast EvaGreen Supermix in Bio-Rad CFX96 PCR
detection system (Bio-Rad). Primer pairs used in this study were listed in
Supplementary Table S5. The relative expression level of each gene was
normalized to the GAPDH expression level of each sample by DDCt
method.
Modulation of miR-26a-2 expression level in LPS cell lines
The effect of overexpression of miR-26a-2 was examined in SW872 and
LPS141 cell lines using pMSCV retroviral expression vector. Briefly, 460 bp
genomic region containing miR-26a-2 coding sequence was amplified by
PCR using the primer set in the Supplementary Table S5. The PCR product
was ligated into the pMSCV vector using BglII and EcoRI.
Retroviral packaging was performed in 293T cells by cotransfecting
pMSCV-miR-26a-2 vector with packaging vectors pCMV-Gag-Pol and
RD114 envelope vector using Profection mammalian transfection system,
according to the manufacturer’s protocol (Promega, Madison, WI, USA).
LPS cell lines were infected with viral supernatant containing either
miR-26a-2 expression vector or empty vector control with 4 mg/ml
polybrene solution. After 48 h, stable clones were selected using
puromycin. The overexpression of miR-26a-2 was validated by qRT-PCR.
The effect of inhibition of miR-26a-2 was examined in LPS141 and LP6
cell lines using miScript anti-hsa-miR-26a-2* miRNA inhibitor oligos and the
control siRNA oligs (Qiagen). LP141 and LP6 cells were transfected with the
oligos at a concentration of 50 nM using jetPRIME siRNA transfection
reagent, according to the manufacturer’s protocol (BIOPARC, Illkirch,
France). After 24 h, the inhibition of miR-26a-2 was validated by qRT-PCR.
Luciferase reporter assay
pGL3-promoter vector containing the miR-26a-2-binding site in 30-UTR
region of the RCBTB1 gene was constructed using primer sets shown in
Supplementary Table S5. To introduce point mutations to the miR-26a-2-
binding site, Quikchange II XL site-directed mutagenesis kit was used,
according to the manufacturer’s protocol (Stratagene, La Jolla, CA, USA).
Cotransfection of pGL3-Promoter-RCBTB1 30-UTR vector and pRL-TK renilla
luciferase vector, along with either miR-26a-2 expression vector or empty
vector control, was performed using Bio-T transfection reagent according
to the manufacturer’s protocol (BioLand LLC, Paramount, CA). After 48 h,
cells were harvested and subjected to dual luciferase assay using Promega
dual luciferase reporter assay kit according to the manufacturer’s protocol.
Modulation of RCBTB1 expression level in LPS cell lines
For overexpression of RCBTB1 gene, pCMT-RCBTB1-HA-tag expression
vector was obtained from Dr Xiaobo Zhou.16 LPS141 and LP6 cells were
transfected with either RCBTB1 expression vector or empty vector control
using jetPRIME DNA transfection reagent according to the manufacturer’s
protocol (BIOPARC). Subsequent experiments were performed after 48 h of
incubation. Expression of RCBTB1 was validated by qRT-PCR and western
blot.
For inhibition studies, pLKO.1-shRCBTB1 lentiviral vectors were con-
structed using the primer sets, as shown in Supplementary Table S5. The
pLKO.1-scrambled shRNA-negative control vector (Addgene plasmid 1864)
was obtained from Addgene (Cambridge, MA, USA).23 Lentiviral packaging
was performed in 293T cells by cotransfecting pLKO.1-shRCBTB1 vectors
with packaging vectors pCMV-Gag-Pol, pRev and RD114 envelope vector,
using Profection mammalian transfection system according to the
manufacturer’s protocol (Promega). LPS cell lines were infected with viral
supernatants of either shRCBTB1 vector or scrambled shRNA vector
control, with 4mg/ml polybrene solution. After 48 h, stable clones
were selected using puromycin. The inhibition of RCBTB1 was validated
by qRT-PCR and western blot.
Western blotting
Western blotting was performed as described previously.24 Primary
antibodies used in the study are listed in Supplementary Table S6.
Cell growth and proliferation assays
Cell growth was measured by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenylte-
trazolium bromide (MTT) assay (Sigma-Aldrich, St Louis, MO, USA), as
described previously.24 Clonogenic ability of the LPS cells was monitored
by soft agar colony-formation assay. A 0.8% base layer was made in 24-well
plates, followed by a 0.7% top layer containing the cell suspension. After
2–3 weeks of incubation, colonies were counted using a dissecting
microscope.
Cell migration assays
For the wound-healing assay, cells were seeded in six-well plates and
incubated until confluence. Scratches were made on the cell monolayer,
and pictures were taken at regular time intervals up to 24 h. ImageJ was
used to measure the gap width.25 For Boyden chamber assay, cells were
cultured in serum-free RPMI media for 48 h prior to harvesting. Boyden
chamber was made by placing cell culture inserts in 24-well plates (8.0-mm
pore size) (BD Biosciences, San Jose, CA, USA). Cells were seeded in the
upper layer of the chamber in serum-free RPMI media, and bottom
chamber was filled with RPMI media with 15% fetal bovine serum.
After 12 h, cells that had migrated through the membrane were counted
after crystal violet staining.
Cell cycle analysis and apoptosis assay
Cell cycle analysis and apoptosis assay were carried out as described
previously.24 For cell cycle analysis, cells were exposed to 0.1mg/ml
nocodazole for 16 h (Sigma-Aldrich). For apoptosis assay, cells were
exposed to 0.5mg/ml nocodazole for 72 h.
In vitro adipocyte differentiation assay
Primer pairs of the adipocyte differentiation marker genes for qRT-PCR
were described by Mariani et al.26
Statistical analysis
For all statistical tests, P-valuep0.05 was considered statistically significant
and marked by a single asterisk (*). P-value less than or equal to 0.001 were
marked by double asterisks (**). Two-tailed Student’s t-test
with unequal variances was used to compare the difference between
two experimental groups. All experiments were repeated at least three
times to ensure accuracy. w2 test was used to determine if the occurrence
of two different CN change events was associated or independent.
Pearson’s correlation test was used to measure the correlation between
the two groups. Correlation coefficient of 0.5 or higher was considered
significant at the 0.05 level. Patients with survival data were subjected to
Kaplan–Meier survival analysis using GraphPad Prism 4.0 (GraphPad
Software Inc, La Jolla, CA).
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